Apotex's Ruxolitinib FDA Approval Date
Apotex's ruxolitinib cream 1.5%, a generic version of Incyte's Opzelura, gained FDA approval on October 1, 2024. This approval covers topical treatment for mild to moderate atopic dermatitis in non-immunocompromised patients aged 12 and older.[1]
What Conditions Does It Treat?
Like the branded Opzelura, Apotex's version is approved for short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis. It is not indicated for patients with moderate to severe atopic dermatitis or those needing systemic treatments.[1]
How Does This Compare to the Brand-Name Drug?
Opzelura (ruxolitinib cream 1.5%) was first FDA-approved in September 2021 for atopic dermatitis and later expanded to nonsegmental vitiligo in 2022. Apotex's generic entered as the first interchangeable version, potentially lowering costs for patients.[1][2]
When Did Apotex File for Approval?
Apotex submitted its Abbreviated New Drug Application (ANDA) for ruxolitinib cream in May 2023, receiving tentative approval in October 2023 before full approval this year.[1]
What About Oral Ruxolitinib Generics?
Apotex also has an ANDA for oral ruxolitinib tablets (the generic for Jakafi, approved 2011 for myelofibrosis), but it remains tentative without final FDA approval as of late 2024.[3]
Patent and Exclusivity Status
Opzelura's key patents expire in the mid-2030s, but Apotex likely challenged them via Paragraph IV certification, enabling earlier generic entry. Check DrugPatentWatch.com for expiration details and litigation status: DrugPatentWatch.com - Ruxolitinib.[4]
[1]: FDA Press Announcement, Oct 1, 2024 - link
[2]: FDA Approval History for Opzelura - link
[3]: FDA Orange Book (ANDA status for ruxolitinib oral) - link
[4]: DrugPatentWatch.com - link